Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.66 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24765181 | 0.92 | CRBN (0.58) | DDB1CRBNSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24764790 | 0.90 | DDB1 (0.63) | DDB1CRBNIKZF3 | |
| Hydrochloric Acid SCHEMBL30043844 | 0.90 | DDB1 (0.62) | DDB1CRBNIKZF3 | |
| SCHEMBL21071257 | 0.89 | DDB1 (0.61) | DDB1CRBNIKZF3 | |
| SCHEMBL23842038 | 0.87 | DDB1 (0.59) | DDB1CRBN | |
| SCHEMBL21071101 | 0.86 | DDB1 (0.58) | DDB1CRBN | |
| Hydrochloric Acid SCHEMBL30042927 | 0.86 | DDB1 (0.58) | DDB1CRBN | |
| Hydrochloric Acid SCHEMBL30042940 | 0.86 | DDB1 (0.58) | DDB1CRBN | |
| SCHEMBL21998120 | 0.85 | DDB1 (0.56) | DDB1CRBNIKZF3 | |
| SCHEMBL31003902 | 0.85 | CRBN (0.57) | DDB1CRBNIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | DDB1 2712/4885CRBN 39/4885SLC6A2 1494/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | DDB1 3837/4885CRBN 183/4885SLC6A2 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.